LENZ THERAPEUTICS, INC. Stock-Based Compensation
LENZ THERAPEUTICS, INC. (LENZ) reported Stock-Based Compensation of $8.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $4.47M, a 57.19% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $4.32M, a 69.04% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.68M, a 125.64% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.47M, a 58.33% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $12.55M, a 97.12% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $6.37M, a 373.94% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $1.34M, a 90.08% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $13.53M, a 71.95% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $8.79M 10-Q · filed 2026-08-11 | $12.47M derived: sum of 3 quarters · filed 2026-08-11 | $15.94M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $4.32M 10-Q · filed 2026-05-11 | $8.00M derived: sum of 2 quarters · filed 2026-05-11 | $11.47M derived: sum of 3 quarters · filed 2026-05-11 | $14.31M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $7.15M derived: sum of 2 quarters · filed 2026-03-24 | $9.99M derived: sum of 3 quarters · filed 2026-08-11 | $12.55M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $3.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.31M derived: sum of 2 quarters · filed 2026-08-11 | $8.87M 10-Q · filed 2025-11-05 | $10.50M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.40M 10-Q · filed 2026-08-11 | $7.03M derived: sum of 3 quarters · filed 2026-08-11 | $9.22M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $2.56M 10-Q · filed 2026-05-11 | $4.18M derived: sum of 2 quarters · filed 2026-05-11 | $6.38M derived: sum of 3 quarters · filed 2026-05-11 | $7.97M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $3.82M derived: sum of 2 quarters · filed 2026-03-24 | $5.42M derived: sum of 3 quarters · filed 2026-03-24 | $6.37M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.79M derived: sum of 2 quarters · filed 2025-11-05 | $4.74M 10-Q · filed 2025-11-05 | $5.25M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $2.54M 10-Q · filed 2025-07-30 | $3.06M derived: sum of 3 quarters · filed 2025-07-30 | $3.56M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2024-03-31 | $947.00K 10-Q · filed 2025-05-07 | $1.47M derived: sum of 2 quarters · filed 2025-05-07 | $1.96M derived: sum of 3 quarters · filed 2025-05-07 | $2.15M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $518.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $1.01M derived: sum of 2 quarters · filed 2025-03-19 | $1.20M derived: sum of 3 quarters · filed 2025-03-19 | $1.34M 10-K · filed 2025-03-19 | $10.57M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $494.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $683.00K derived: sum of 2 quarters · filed 2024-11-06 | $825.00K 10-Q · filed 2024-11-06 | $8.27M 10-Q · filed 2023-11-13 | $4.45M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $331.00K 10-Q · filed 2024-08-14 | $6.11M 10-Q · filed 2023-08-14 | $3.95M derived: sum of 3 quarters · filed 2024-08-14 | $7.16M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $142.00K 10-Q · filed 2024-05-08 | $3.26M 10-Q · filed 2023-05-11 | $3.76M derived: sum of 2 quarters · filed 2024-05-08 | $6.97M derived: sum of 3 quarters · filed 2024-05-08 | $10.33M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $6.83M derived: sum of 2 quarters · filed 2024-02-27 | $10.19M derived: sum of 3 quarters · filed 2024-02-27 | $13.53M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $6.57M derived: sum of 2 quarters · filed 2023-11-13 | $9.91M 10-Q · filed 2023-11-13 | $12.36M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $6.70M 10-Q · filed 2023-08-14 | $9.15M derived: sum of 3 quarters · filed 2023-08-14 | $11.52M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $3.34M 10-Q · filed 2023-05-11 | $5.79M derived: sum of 2 quarters · filed 2023-05-11 | $8.16M derived: sum of 3 quarters · filed 2023-05-11 | $10.18M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $4.82M derived: sum of 2 quarters · filed 2023-03-20 | $6.84M derived: sum of 3 quarters · filed 2023-03-20 | $7.87M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | $2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.39M derived: sum of 2 quarters · filed 2022-11-09 | $5.42M 10-Q · filed 2022-11-09 | $5.57M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.05M 10-Q · filed 2022-08-11 | $3.19M derived: sum of 3 quarters · filed 2022-08-11 | $3.23M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.03M 10-Q · filed 2022-05-12 | $1.17M derived: sum of 2 quarters · filed 2022-05-12 | $1.21M derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $176.00K derived: sum of 2 quarters · filed 2022-03-21 | $177.00K 10-K · filed 2022-03-21 | |||||
| 2020-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $37.00K 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $1.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |